Partial omission of bleomycin for early‐stage Hodgkin lymphoma patients treated with combined modality therapy: Does incomplete ABVD lead to inferior outcomes?

Classical Hodgkin lymphoma (HL) patients achieve excellent outcomes; therefore, treatment de‐escalation strategies to spare toxicity have been prioritized. In a large randomized trial of early‐stage HL patients, omission of chemotherapeutic agents including bleomycin from the standard ABVD (doxorubi...

Descripción completa

Detalles Bibliográficos
Autores principales: Gunther, Jillian R., Pinnix, Chelsea C., Glober, Gordon R., Christopherson, Kaitlin M., Fang, Penny, Lee, Hun Ju, Ahmed, Sairah, Steiner, Raphael E., Nair, Ranjit, Strati, Paolo, Neelapu, Sattva S., Nastoupil, Loretta J., Dabaja, Bouthaina S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Short Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7455016/
https://www.ncbi.nlm.nih.gov/pubmed/32864660
http://dx.doi.org/10.1002/jha2.1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7455016/
https://www.ncbi.nlm.nih.gov/pubmed/32864660
http://dx.doi.org/10.1002/jha2.1

Ejemplares similares